Part 2/9:
Recently, Eli Lilly—one of the world's leading companies in obesity medication—announced a groundbreaking $1.3 billion deal with Superliminal Medicines. This partnership centers around the discovery of AI-driven medicines for obesity, signaling a major shift in pharmaceutical research and development. Such hefty investments underscore the industry's belief in AI's potential to accelerate drug discovery and reduce expenses.